
Discover our story - told by trusted sources!

ANTIVIRAL ACTIVITY OF THE EXTRACELLULAR MATRIX MULTI-TISSUE PLATFORM® (MTP) AGAINST FILOVIRUS AND MONKEYPOX VIRUS
As an FDA-cleared product with an established safety record in open wound settings, these in vitro results support further testing in vivo. Furthermore, several tests (including VZV, HSV 1/2, PrV, X-MulLV, and SARS-COV2) were conducted on both MTP Gel and MTP Powder with comparable results, suggesting that further formulation work (e.g., nasal spray, inhalable powder or aerosol, ophthalmic solution) is reasonable.

Antiviral Action of FetTech’s Multi-Tissue Platform (MTP) Powder and Gel
Enveloped viruses, or viruses with lipid bilayer membranes on the outer part of the virus, are responsible for some of the most common infections known to mankind. while infections resulting from enveloped viruses are typically less severe than non-enveloped relatives, enveloped viruses are responsible for some of the deadliest epidemics and pandemics in human history.

The extracellular matrix multi-tissue platform (MTP), has broad-spectrum antiviral activity and prevents varicella zoster virus in cells and human skin
We presented our latest study at the ICAR2024 virology conference, in Australia. Our guest attendee presented their findings and results, and we are finally ready to share our findings with you.